Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer a review of the clinical effectiveness
With all the anaplastic lymphoma kinase inhibitors (ALKIs) available in the market, it is important to understand the comparative clinical effectiveness and safety profile of the different ALKIs in relation to each other, particularly in the first-line and second-line setting. This report was undert...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, November 1, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | With all the anaplastic lymphoma kinase inhibitors (ALKIs) available in the market, it is important to understand the comparative clinical effectiveness and safety profile of the different ALKIs in relation to each other, particularly in the first-line and second-line setting. This report was undertaken to examine the current evidence surrounding the comparative clinical benefits of first-line ALKIs among patients naive to previous anaplastic lymphoma kinase (ALK) treatment (ALK-naive), and second-line ALKIs among patients who have been pretreated with other ALKIs and had disease progression (ALK-pretreated) |
|---|---|
| Physical Description: | 1 PDF file (32 pages) illustrations |